Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting

Nov 25, 2024 - financialpost.com
Rakovina Therapeutics Inc., a biopharmaceutical company, has presented initial results of its Deep Docking Artificial Intelligence (AI) drug discovery screening at the Society for Neuro-Oncology Annual Meeting. The research focused on the discovery of novel PARP1-Selective Inhibitors for use against brain tumors, with the AI technology enabling rapid virtual screening of multi-billion compounds to identify selective inhibitors of PARP-1, a key enzyme involved in DNA repair and brain cancer progression.

The company's innovative approach aims to improve the efficiency of drug discovery and enhance the specificity and efficacy of potential therapeutics. The next step for Rakovina Therapeutics is to select a lead candidate molecule based on wet lab validation for target selectivity, metabolic and pharmacokinetic parameters, CNS penetration, and activity against cancer.

Key takeaways:

  • Rakovina Therapeutics presented initial results of its Deep Docking Artificial Intelligence (AI) drug discovery screening at the Society for Neuro-Oncology (SNO) Annual Meeting.
  • The presentation highlighted the use of AI in identifying selective inhibitors of PARP-1, a key enzyme involved in DNA repair and brain cancer progression.
  • The company's innovative approach aims to improve the efficiency of drug discovery and enhance the specificity and efficacy of potential therapeutics.
  • Rakovina Therapeutics is planning to select a lead candidate molecule based on wet lab validation for target selectivity, metabolic and pharmacokinetic parameters, CNS penetration, and activity against cancer.
View Full Article

Comments (0)

Be the first to comment!